Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers
Poly (ADP-ribose) polymerase (PARP) inhibitors and platinum-based chemotherapies have been found to be particularly effective in tumors that harbor deleterious germline or somatic mutations in the BRCA1 or BRCA2 genes, the products of which contribute to the conservative homologous recombination repair of DNA double-strand breaks. Nonetheless, several setbacks in clinical trial settings have highlighted some of the issues surrounding the investigation of PARP inhibitors, especially the identification of patients who stand to benefit from such drugs. One potential approach to finding this patient subpopulation is to examine...
Source: Breast Cancer Research - June 3, 2014 Category: Cancer & Oncology Authors: Johnathan WatkinsSheeba IrshadAnita GrigoriadisAndrew Tutt Source Type: research
An integrated genomic approach identifies persistent tumor suppressive effects of transforming growth factor-beta in human breast cancer
Conclusions:
Tumor suppressive effects of TGF-beta persist in some breast cancer patients at the time of surgery and affect clinical outcome. Carefully tailored in vitro/in vivo genomic approaches can identify such patients for exclusion from treatment with TGF-beta antagonists. (Source: Breast Cancer Research)
Source: Breast Cancer Research - June 2, 2014 Category: Cancer & Oncology Authors: Misako SatoMitsutaka KadotaBinwu TangHoward YangYu-an YangMengge ShanJia WengMichael WelshKathleen FlandersYoshiko NaganoAleksandra MichalowskiRobert CliffordMaxwell LeeLalage Wakefield Source Type: research
JMJD2A contributes to breast cancer progression through transcriptional repression of the tumor suppressor ARHI
Conclusion:
We demonstrated a cancer-promoting effect of JMJD2A and defined a novel molecular pathway contributing to JMJD2A-mediated breast cancer progression. (Source: Breast Cancer Research)
Source: Breast Cancer Research - May 30, 2014 Category: Cancer & Oncology Authors: Li-Liang LiAi-Min XueBei-Xu LiYi-Wen ShenYu-Hua LiCheng-Liang LuoMing-Chang ZhangJie-Qing JiangZu-De XuJian-Hui XieZi-Qin Zhao Source Type: research
Survivin family proteins as novel molecular determinants of doxorubicin resistance in organotypic human breast tumors
Conclusion:
Survivin family proteins are novel effectors of doxorubicin resistance in chemotherapy-naive breast cancer. The incorporation of survivin antagonist(s) in anthracycline-containing regimens may have improved clinical activity in these patients. (Source: Breast Cancer Research)
Source: Breast Cancer Research - May 30, 2014 Category: Cancer & Oncology Authors: Alice FaversaniValentina VairaGiacomina MoroDelfina TosiAlessia LopergoloDavid SchultzDayana RivadeneiraDario AltieriSilvano Bosari Source Type: research
C-X-C motif chemokine 12/C-X-C chemokine receptor type 7 signaling regulates breast cancer growth and metastasis by modulating the tumor microenvironment
Conclusion:
These observations reveal that CXCR7 enhances breast cancer growth and metastasis via a novel pathway by modulating the tumor microenvironment. These findings indentify CXCR7-mediated STAT3 activation and modulation of tumor microenvironment as novel regulation of breast cancer growth and metastasis. These studies indicate that new strategies using CXCR7 inhibitors could be developed for anti-metastatic therapy. (Source: Breast Cancer Research)
Source: Breast Cancer Research - May 29, 2014 Category: Cancer & Oncology Authors: Nissar WaniMohd NasserDinesh AhirwarHelong ZhaoZhenhua MiaoKonstantin ShiloRamesh Ganju Source Type: research
